Stay updated with breaking news from Outcomes Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AstraZeneca on Friday said it would discontinue two late-stage trials looking at the potential benefits of its drug Lokelma in the management of hyperkalaemia across the cardiorenal spectrum. ...
AstraZeneca discontinues STABILIZE-CKD and DIALIZE-Outcomes Phase III trials
A2725v FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...
FTSE 100 up 43 points at 7,497 House prices rise 0.2% in November Miners jump on positive China data 13:08pm: Pfizer shares dip on obesity pill setback A...
AstraZeneca Plc AZN discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was…